An important amino acid called methionine aids in the livers breakdown of lipids, reducing fat buildup in your body
Injectable BPC-157 used in pre-clinical animal research and in off-label clinical settings typically involves higher doses and subcutaneous or intraperitoneal administration
Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose
However, it should be used under medical supervision, especially considering potential side effects and underlying health conditions
Journal (Pharmaceuticals, Sep 28, 2025, 18(10), 1450)